SCHEMBL13064978

SCHEMBL13064978

Cc1ccc(Nc2c(C(=O)O)cc(O)c(O)c2O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 3/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
AKR1C3 P42330 2/20 0.49
XDH P47989 1/20 0.48
SLC22A12 Q96S37 1/20 0.48
CSNK2A1 P68400 1/20 0.47
MCL1 Q07820 2/20 0.46
GAA P10253 2/20 0.46
G6PD P11413 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13064983 0.84 SNCA (0.47) MEN1KMT2AMCL1GAAG6PD
SCHEMBL13064980 0.83 KDM1A (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL5693236 0.79 SMN1; SMN2 (0.57) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL936023 0.74 AKR1C3 (0.69) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL9409077 0.74 AKR1C3 (0.64) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL27837898 0.72 AKR1C3 (0.52) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL9592992 0.71 AKR1C3 (0.72) AKR1C2SMN1; SMN2AKR1C3XDHSLC22A12
SCHEMBL9593414 0.71 AKR1C3 (0.74) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL1325561 0.71 SELL (0.45) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3
SCHEMBL8976069 0.70 AKR1C3 (0.72) AKR1C2MEN1KMT2ASMN1; SMN2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9052324-B2 Compounds and assays for controlling Wnt activity ENZO BIOCHEM, INC. (US) 2015-06-09 US disclosed
US-20120322717-A9 Compounds and assays for controlling Wnt activity ENZO BIOCHEM, INC. 2012-12-20 US disclosed
US-20100298200-A1 Compounds and assays for controlling Wnt activity LIU DAKAI 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322717-A9 Compounds and assays for controlling Wnt activity WNT1, WNT3A, WNT3 AKR1C2 3981/4885MEN1 3364/4885KMT2A 4381/4885
US-20100298200-A1 Compounds and assays for controlling Wnt activity WNT1, WNT3A, WNT3 AKR1C2 3981/4885MEN1 3364/4885KMT2A 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.